NASDAQ:EVAX - Nasdaq - US29970R3030 - ADR - Currency: USD
Overall EVAX gets a fundamental rating of 2 out of 10. We evaluated EVAX against 555 industry peers in the Biotechnology industry. Both the profitability and financial health of EVAX have multiple concerns. EVAX is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -84.65% | ||
ROE | N/A | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | N/A | ||
Debt/FCF | N/A | ||
Altman-Z | -3.9 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.01 | ||
Quick Ratio | 2.01 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
2.47
-0.01 (-0.4%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 4.67 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | N/A | ||
P/tB | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -84.65% | ||
ROE | N/A | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | N/A | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 0% | ||
Cap/Sales | 0% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.01 | ||
Quick Ratio | 2.01 | ||
Altman-Z | -3.9 |